BACKGROUND:Acute otitis media (AOM) is a common childhood illness and the leading indication for antibiotic prescriptions for US children. Xylitol, a naturally occurring sugar alcohol, can reduce AOM when given 5 times per day as a gum or syrup, but a more convenient dosing regimen is needed for widespread adoption. METHODS: We designed a pragmatic practice-based randomized controlled trial to determine if viscous xylitol solution at a dose of 5 g 3 times per day could reduce the occurrence of clinically diagnosed AOM among otitis-prone children 6 months through 5 years of age. RESULTS:A total of 326 subjects were enrolled, with 160 allocated toxylitol and 166 to placebo. In the primary analysis of time to first clinically diagnosed AOM episode, the hazard ratio for xylitol versus placebo recipients was 0.88 (95% confidence interval [CI] 0.61 to 1.3). In secondary analyses, the incidence of AOM was 0.53 episodes per 90 days in the xylitol group versus 0.59 in the placebo group (difference 0.06; 95% CI -0.25 to 0.13); total antibiotic use was 6.8 days per 90 days in the xylitol group versus 6.4 in the placebo group (difference 0.4; 95% CI -1.8 to 2.7). The lack of effectiveness was not explained by nonadherence to treatment, as the hazard ratio for those taking nearly all assigned xylitol compared with those taking none was 0.93 (95% CI 0.56 to 1.57). CONCLUSIONS:Viscous xylitol solution in a dose of 5 g 3 times per day was ineffective in reducing clinically diagnosed AOM among otitis-prone children.
RCT Entities:
BACKGROUND: Acute otitis media (AOM) is a common childhood illness and the leading indication for antibiotic prescriptions for US children. Xylitol, a naturally occurring sugar alcohol, can reduce AOM when given 5 times per day as a gum or syrup, but a more convenient dosing regimen is needed for widespread adoption. METHODS: We designed a pragmatic practice-based randomized controlled trial to determine if viscous xylitol solution at a dose of 5 g 3 times per day could reduce the occurrence of clinically diagnosed AOM among otitis-prone children 6 months through 5 years of age. RESULTS: A total of 326 subjects were enrolled, with 160 allocated to xylitol and 166 to placebo. In the primary analysis of time to first clinically diagnosed AOM episode, the hazard ratio for xylitol versus placebo recipients was 0.88 (95% confidence interval [CI] 0.61 to 1.3). In secondary analyses, the incidence of AOM was 0.53 episodes per 90 days in the xylitol group versus 0.59 in the placebo group (difference 0.06; 95% CI -0.25 to 0.13); total antibiotic use was 6.8 days per 90 days in the xylitol group versus 6.4 in the placebo group (difference 0.4; 95% CI -1.8 to 2.7). The lack of effectiveness was not explained by nonadherence to treatment, as the hazard ratio for those taking nearly all assigned xylitol compared with those taking none was 0.93 (95% CI 0.56 to 1.57). CONCLUSIONS: Viscous xylitol solution in a dose of 5 g 3 times per day was ineffective in reducing clinically diagnosed AOM among otitis-prone children.
Authors: Craig I Coleman; Brendan Limone; Diana M Sobieraj; Soyon Lee; Matthew S Roberts; Rajbir Kaur; Tawfikul Alam Journal: J Manag Care Pharm Date: 2012-09
Authors: T Tapiainen; T Kontiokari; L Sammalkivi; I Ikäheimo; M Koskela; M Uhari Journal: Antimicrob Agents Chemother Date: 2001-01 Impact factor: 5.191
Authors: K K Mäkinen; C A Bennett; P P Hujoel; P J Isokangas; K P Isotupa; H R Pape; P L Mäkinen Journal: J Dent Res Date: 1995-12 Impact factor: 6.116
Authors: E T Rhodes; L Vernacchio; A A Mitchell; C Fischer; P Giacalone; D S Ludwig; C B Ebbeling Journal: Pediatr Obes Date: 2016-08-05 Impact factor: 4.000
Authors: Nav Persaud; Andreas Laupacis; Amir Azarpazhooh; Catherine Birken; Jeffrey S Hoch; Wanrudee Isaranuwatchai; Jonathan L Maguire; Muhammad M Mamdani; Kevin Thorpe; Christopher Allen; Dalah Mason; Christine Kowal; Farnaz Bazeghi; Patricia Parkin Journal: BMJ Open Date: 2018-08-05 Impact factor: 2.692
Authors: Anne G M Schilder; Tasnee Chonmaitree; Allan W Cripps; Richard M Rosenfeld; Margaretha L Casselbrant; Mark P Haggard; Roderick P Venekamp Journal: Nat Rev Dis Primers Date: 2016-09-08 Impact factor: 52.329